Navigation Links
ACORN's Success in Delivering Top Quality Research Portfolio to Community-Based Oncology Practices Presented at Annual Investigator Meeting

MEMPHIS, Tenn., March 2 /PRNewswire-USNewswire/ -- Accelerated Community Oncology Research Network (ACORN(TM)), an oncology focused research network, announced today the highlights of its annual Principal Investigators' Meeting held in Scottsdale, AZ in February. Medical oncologists from community-based oncology practices throughout the United States met to discuss the latest cancer research advances, emerging treatment trends, as well as promising new molecules in the drug pipeline.

(Logo: )

2008 represented a banner year for ACORN and its network members. 74 different sponsors, representing 93 industry-sponsored trials, engaged the ACORN Network. Additionally, 21 ACORN investigator initiated trials were open in 2008. The ACORN portfolio included studies of 41 different investigational agents in 2008. 62% of ACORN's 2008 studies were Phase II with the majority of the trials focusing on cancers of the lung, breast, ovary, colon/rectum, or pancreas. ACORN also delivered research opportunities for less frequently seen cancers to its member practices to make treatments of all cancer types available.

"Commitment to research excellence is integral to the ACORN process as is thorough education of all staff members. We continue to identify new processes to facilitate rapid deployment of clinical trials to community-based oncology practices while experiencing banner growth," remarked Edward J. Stepanski, PhD, COO, ACORN.

Practicing oncologists in the ACORN Network serve as Tumor Committee Chairs. Those presenting at the 2009 Meeting included Mark Keaton, MD, Augusta Oncology Associates, Augusta, GA, Gastroenterology; Lee Schwartzberg, MD, FACP, The West Clinic, Memphis, TN, Breast Cancer; Frederick Schnell, MD, FACP, Central Georgia Cancer Care, Macon, GA, Lymphoma; Brian Samuels, MD, FACP, FCP(SA), Kootenai Cancer Center, Coeur d'Alene, ID, Melanoma, Sarcoma, and Rare Cancer Trials; Johnetta Blakely, MD, The West Clinic, Memphis, TN, Phase 1 Trials; David Henry, MD, Pennsylvania Oncology Hematology Associates, Philadelphia, PA, Supportive Care Trials; and Brad Somer, MD, The West Clinic, Memphis, TN, Genitourinary Trials.

The ACORN Network seeks to make clinical research an integral part of community-based cancer care by giving every patient an equal opportunity to participate in clinical research. By making research a vital part of clinical operations and using technology to streamline the process, ACORN enhances the speed, accuracy, and productivity of clinical trial operations. More rapid development time for new agents results in providing more effective care to benefit patients faster than previously possible. ACORN provides Contracting, Budgeting, Regulatory Affairs, Project Management, Data Management, Quality Assurance, Statistical Analysis, Medical Writing, and Site Development to its participating members and pharmaceutical sponsors.

"In 2009, ACORN will accelerate its commitment to oncology research by expanding opportunities for both members and sponsors," announced Lee S. Schwartzberg, MD, FACP, President of ACORN.

For additional information, contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878 or visit

Accelerated Community Oncology Research Network, Inc.(TM) (ACORN)

ACORN focuses on oncology exclusively. ACORN offers centralized clinical trial services, scientific analysis, and is a full-service Contract Research Organization (CRO), providing contract and budgeting services; fostering accrual of subjects at the site level; collecting data and monitoring its accuracy; and working seamlessly with both trial sponsors and participating practices.

    Contact Information:
    Liz Conway
    (901) 435-5570

    Deborah D. Coble
    901-683-0055 x1312

SOURCE Accelerated Community Oncology Research Network, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kenyan malaria success strengthens call for free insecticide-treated nets for all
2. Eligard(R) six-month formulation successfully completes European approval procedure
3. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
4. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
5. Texas Largest Physician Carrier Announces 5th Successive Rate Cut on Anniversary of Lawsuit Reform
6. Bacteria successful in cancer treatment
7. Congress Poised to Add Millions of Uninsured Children to Successful, Bipartisan Health Plan
8. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
9. Success of Shape Up Somerville childhood obesity intervention to be presented
10. Cell growth technology promises more successful drug development
11. CIGNA Group Insurance Celebrates Return to Work Success During National Rehabilitation Awareness Week
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology: